US2021052219A1PendingUtilityA1

Pump homeostasis indicator (phi)

Assignee: HEARTWARE INCPriority: Jul 13, 2017Filed: Nov 5, 2020Published: Feb 25, 2021
Est. expiryJul 13, 2037(~11 yrs left)· nominal 20-yr term from priority
A61M 60/538A61M 60/515A61M 60/216A61M 60/178A61M 2205/3365A61B 5/7278A61B 5/02405A61B 5/746A61M 2205/18A61M 2205/04A61B 5/02028A61B 5/02007A61B 5/4851A61B 5/02042A61M 1/101A61M 1/1086
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method determining adverse events from operation of an implantable blood pump including calculating a moving average convergence divergence (MACD) based on power consumed by the implantable blood pump to maintain a constant rotational speed of an impeller of the implantable blood pump. An alert is generated when the calculated MACD diverges from a predetermined MACD threshold and a predetermined MACD zero-crossing time threshold.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of determining adverse events from operation of an implantable blood pump, comprising:
 calculating a first average power consumed by the implantable blood pump to maintain a constant rotational speed of an impeller of the implantable blood pump measured at a predetermined interval for a first predetermined period of time;   calculating a second average power consumed by the implantable blood pump to maintain a constant rotational speed of an impeller of the implantable blood pump measured at the predetermined interval for a second predetermined period of time greater than the first period of time; and   generating an alert when the calculated first average power consumed by the implantable blood pump deviates from the calculated second average power consumed by the implantable blood pump by two standard deviations.   
     
     
         2 . The method of  claim 1 , wherein the method further includes clearing the alert when the first average power consumed by the implantable blood pump converges to the calculated second average power consumed by the implantable blood pump by less than two standard deviations. 
     
     
         3 . The method of  claim 1 , wherein generating the alert is indicative of at least one from the group consisting of thrombus, gastrointestinal bleeding, tachycardia, arrhythmia, and right heart failure. 
     
     
         4 . The method of  claim 1 , wherein the first predetermined period of time is between 1-3 hours and the second predetermined period of time is between 1-5 days.

Join the waitlist — get patent alerts

Track US2021052219A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.